For the year ending 2025-12-31, RYTM made $189,757K in revenue. -$202,674K in net income. Net profit margin of -106.81%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 189,757 | 130,126 | ||
| Cost of sales | 19,492 | 13,368 | ||
| Research and development | 167,340 | 237,957 | ||
| Selling, general, and administrative | 194,941 | 144,304 | ||
| Total costs and expenses | 381,773 | 395,629 | ||
| Loss from operations | -192,016 | -265,503 | ||
| Other income, net | 1,264 | 2,239 | ||
| Gain on settlement of forward contract | 0 | 8,900 | ||
| Interest expense | 20,583 | 20,603 | ||
| Interest income | 15,293 | 14,711 | ||
| Total other income (expense), net | -4,026 | 5,247 | ||
| Loss before income taxes | -196,042 | -260,256 | ||
| Provision for income taxes | 497 | 346 | ||
| Net loss | -196,539 | -260,602 | ||
| Accrued dividends on convertible preferred stock | 5,378 | 3,970 | ||
| Net loss attributable to common stockholders | -201,917 | -264,572 | ||
| Foreign currency translation adjustment | -1,261 | - | ||
| Unrealized (loss) gain, net on marketable securities, net of tax | 504 | - | ||
| Comprehensive loss | -202,674 | - | ||
| Basic EPS | -3.11 | -4.34 | ||
| Diluted EPS | -3.11 | -4.34 | ||
| Basic Average Shares | 64,984,361 | 60,995,204 | ||
| Diluted Average Shares | 64,984,361 | 60,995,204 | ||
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)